SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pfeiffer Per)
 

Sökning: WFRF:(Pfeiffer Per) > Consequences of a h...

  • Aasebö, Kristine Ö.Univ Bergen, Dept Clin Sci, Bergen, Norway (författare)

Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors : A population-based cohort of metastatic colorectal cancer patients

  • Artikel/kapitelEngelska2019

Förlag, utgivningsår, omfång ...

  • 2019-05-09
  • WILEY,2019
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-391954
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-391954URI
  • https://doi.org/10.1002/cam4.2205DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Immunotherapy for patients with microsatellite-instable (MSI-H) tumors or BRAF-inhibitors combination treatment for BRAF-mutated (mutBRAF) tumors in metastatic colorectal cancer (mCRC) is promising, but the frequency of these molecular changes in trial patients are low. Unselected population-based studies of these molecular changes are warranted.Methods: A population-based cohort of 798 mCRC patients in Scandinavia was studied. Patient and molecular tumor characteristics, overall survival (OS) and progression-free survival (PFS) were estimated.Results: Here, 40/583 (7%) tumor samples were MSI-H and 120/591 (20%) were mutBRAF; 87% of MSI-H tumors were mutBRAF (non-Lynch). Elderly (>75 years) had more often MSI-H (10% vs 6%) and MSI-H/mutBRAF (9% vs 4%) tumors. Response rate (5% vs 44%), PFS (4 vs 8 months), and OS (9 vs 18 months) after first-line chemotherapy was all significantly lower in patients with MSI-H compared to patients with microsatellite stable tumors. MSI-H and mutBRAF were both independent poor prognostic predictors for OS (P = 0.049, P < 0.001) and PFS (P = 0.045, P = 0.005) after first-line chemotherapy. Patients with MSI-H tumors received less second-line chemotherapy (15% vs 37%, P = 0.005).Conclusions: In unselected mCRC patients, MSI-H and mutBRAF cases were more common than previously reported. Patients with MSI-H tumors had worse survival, less benefit from chemotherapy, and they differed considerably from recent third-line immunotherapy trial patients as they were older and most had mutBRAF tumor (non-Lynch).

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Dragomir, AncaUppsala universitet,Klinisk och experimentell patologi,Fredrik Pontén(Swepub:uu)ancadrag (författare)
  • Sundström, MagnusUppsala universitet,Klinisk och experimentell patologi(Swepub:uu)magnsund (författare)
  • Mezheyeuski, ArturUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)artme913 (författare)
  • Edqvist, Per-Henrik DUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)peedq227 (författare)
  • Eide, Geir EgilUniv Bergen, Dept Global Publ Hlth & Primary Care, Lifestyle Epidemiol Grp, Bergen, Norway;Haukeland Hosp, Ctr Clin Res, Bergen, Norway (författare)
  • Pontén, FredrikUppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk och experimentell patologi(Swepub:uu)fredpont (författare)
  • Pfeiffer, PerOdense Univ Hosp, Dept Oncol, Odense, Denmark (författare)
  • Glimelius, BengtUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)bengglim (författare)
  • Sorbye, HalfdanUniv Bergen, Dept Clin Sci, Bergen, Norway;Haukeland Hosp, Dept Oncol, Bergen, Norway (författare)
  • Univ Bergen, Dept Clin Sci, Bergen, NorwayKlinisk och experimentell patologi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Cancer Medicine: WILEY8:7, s. 3623-36352045-7634

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy